CLDI · Insider Trading
Calidi Biotherapeutics, Inc.
Every open-market purchase and sale reported by CLDI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Eric E Poma | Chief Executive Officer | A | +32,000 deriv. | — |
| 2026-08-19 | Andrew C. Jackson | Chief Financial Officer | A | +14,000 deriv. | — |
| 2026-08-19 | Alan R. Stewart | Director | A | +4,000 deriv. | — |
| 2026-08-19 | George Peoples | Director | A | +4,000 deriv. | — |
| 2026-08-19 | Santidrian Antonio Fernandez | Chief Scientific Officer | A | +16,000 deriv. | — |
| 2026-08-19 | Scott Leftwich | Director | A | +4,000 deriv. | — |
| 2026-08-19 | Corazon (Corsee) D. Sanders | Director | A | +6,000 deriv. | — |
| 2026-08-19 | James A Schoeneck | Director | A | +5,000 deriv. | — |
| 2025-12-16 | Allan Camaisa | Director | Sell | −850 | −$1.24K |
| 2025-09-05 | Santidrian Antonio Fernandez | Chief Scientific Officer | A | +35,000 deriv. | — |
| 2025-09-05 | Eric E Poma | Chief Executive Officer | A | +10,000 deriv. | — |
| 2025-09-05 | Andrew C. Jackson | Chief Financial Officer | A | +30,000 deriv. | — |
| 2025-08-25 | Andrew C. Jackson | Chief Financial Officer | Buy | +2,500 | +$5.00K |
| 2025-08-25 | James A Schoeneck | Director | Buy | +75,000 | +$150.00K |
| 2025-08-25 | Eric E Poma | Chief Executive Officer | Buy | +25,000 | +$50.00K |
| 2025-08-25 | Scott Leftwich | Director | Buy | +125,000 | +$250.00K |
| 2025-07-15 | Alan R. Stewart | Director | A | +137,078 deriv. | — |
| 2025-07-15 | James A Schoeneck | Director | A | +164,493 deriv. | — |
| 2025-07-15 | George Peoples | Director | A | +137,078 deriv. | — |
| 2025-07-15 | Scott Leftwich | Director | A | +137,078 deriv. | — |
| 2025-04-25 | Eric E Poma | Chief Executive Officer | A | +726,412 deriv. | — |
| 2025-01-03 | Scott Leftwich | Director | A | +11,684 | — |
| 2025-01-03 | Alan R. Stewart | Director | A | +12,771 | — |
| 2024-12-18 | Allan Camaisa | CEO and Chairman of the Board | Sell | −10,000 | −$16.20K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Scott Leftwich | Director | 8,248 | $5.28K |
| James A Schoeneck | Director | 5,260 | $3.37K |
| Allan Camaisa | CEO and Chairman of the Board | 5,157 | $3.30K |
| Eric E Poma | Chief Executive Officer | 1,562 | $1000 |
| Andrew C. Jackson | Chief Financial Officer | 156 | $100 |
| Alan R. Stewart | Director | 151 | $97 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CLDI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.